Cantor Fitzgerald Investment Advisors L.P. Sells 23,911 Shares of Medtronic PLC $MDT

Key Points

• Cantor Fitzgerald Investment Advisors L.P. reduced its Medtronic stake by 12.8% in Q4, selling 23,911 shares and leaving 163,115 shares valued at about $15.67 million (≈1.2% of its portfolio, its 24th largest holding).
• EVP Harry Skip Kiil sold 52,524 Medtronic shares on Feb. 19 at an average $97.71 for roughly $5.13 million, cutting his personal ownership by about 61.6% to 32,768 shares.
• Medtronic slightly beat quarterly estimates (EPS $1.36 vs $1.34; revenue $9.02B vs $8.89B), set FY2026 EPS guidance of $5.62–$5.66, and announced a $0.71 quarterly dividend (3.3% yield; ex-dividend Mar. 27).

Cantor Fitzgerald Investment Advisors L.P. lessened its stake in Medtronic PLC (NYSE:MDT - Free Report) by 12.8% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 163,115 shares of the medical technology company's stock after selling 23,911 shares during the quarter. Medtronic comprises about 1.2% of Cantor Fitzgerald Investment Advisors L.P.'s investment portfolio, making the stock its 24th largest holding. Cantor Fitzgerald Investment Advisors L.P.'s holdings in Medtronic were worth $15,669,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Brighton Jones LLC grew its stake in Medtronic by 1,368.0% in the fourth quarter. Brighton Jones LLC now owns 39,989 shares of the medical technology company's stock valued at $3,194,000 after acquiring an additional 37,265 shares during the period. Sivia Capital Partners LLC grew its stake in Medtronic by 9.6% in the second quarter. Sivia Capital Partners LLC now owns 4,356 shares of the medical technology company's stock valued at $380,000 after acquiring an additional 381 shares during the period. Jump Financial LLC acquired a new position in Medtronic in the second quarter valued at about $299,000. Faithward Advisors LLC grew its stake in Medtronic by 3.1% in the second quarter. Faithward Advisors LLC now owns 5,026 shares of the medical technology company's stock valued at $438,000 after acquiring an additional 151 shares during the period. Finally, Treasurer of the State of North Carolina grew its stake in Medtronic by 37.4% in the second quarter. Treasurer of the State of North Carolina now owns 1,001,922 shares of the medical technology company's stock valued at $87,338,000 after acquiring an additional 272,536 shares during the period. Institutional investors own 82.06% of the company's stock.

Insider Transactions at Medtronic

In related news, EVP Harry Skip Kiil sold 52,524 shares of the company's stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the sale, the executive vice president owned 32,768 shares in the company, valued at approximately $3,201,761.28. This represents a 61.58% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 0.26% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on MDT. CICC Research began coverage on Medtronic in a research note on Friday, January 30th. They issued an "outperform" rating for the company. Weiss Ratings reissued a "buy (b-)" rating on shares of Medtronic in a research note on Monday, December 29th. Needham & Company LLC restated a "buy" rating and issued a $120.00 price target on shares of Medtronic in a report on Thursday, March 26th. Sanford C. Bernstein boosted their price target on Medtronic from $111.00 to $112.00 and gave the company an "outperform" rating in a report on Friday, January 9th. Finally, Robert W. Baird cut their price target on Medtronic from $103.00 to $100.00 and set a "neutral" rating on the stock in a report on Wednesday, February 18th. One research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and ten have issued a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $109.00.

Medtronic Stock Performance

Shares of Medtronic stock opened at $87.17 on Friday. The firm has a market cap of $111.91 billion, a price-to-earnings ratio of 24.28, a price-to-earnings-growth ratio of 2.28 and a beta of 0.75. The stock's 50-day moving average is $93.08 and its 200-day moving average is $95.96. Medtronic PLC has a one year low of $79.93 and a one year high of $106.33. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.54 and a quick ratio of 1.87.

Medtronic (NYSE:MDT - Get Free Report) last issued its quarterly earnings results on Tuesday, February 17th. The medical technology company reported $1.36 EPS for the quarter, beating analysts' consensus estimates of $1.34 by $0.02. The company had revenue of $9.02 billion for the quarter, compared to analyst estimates of $8.89 billion. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.The company's quarterly revenue was up 5.8% compared to the same quarter last year. During the same period in the previous year, the company posted $1.38 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Equities analysts predict that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, April 17th. Investors of record on Friday, March 27th will be issued a dividend of $0.71 per share. This represents a $2.84 annualized dividend and a yield of 3.3%. The ex-dividend date is Friday, March 27th. Medtronic's dividend payout ratio is presently 79.11%.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic's offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).

Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic PLC (NYSE:MDT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.